177Lu-AB-3PRGD2

N/A

Report date: 2025/11/20 16:05:05

Base Information

Drug Name177Lu-AB-3PRGD2

Drug Alias Name177Lu-AB-3PRGD2

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionIntegrin alpha-V/beta-3 modulators

TargetsIntegrin alpha-V/beta-3

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesPeking Union Medical College Hospital

China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Xiamen University

Inactive CompaniesPeking Union Medical College Hospital

Active IndicationsSolid tumours

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A